V M Quintana1, N I Torres, M B Wachsman, P J Sinko, V Castilla, M Chikindas. 1. Laboratorio de Virología, Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Universitaria, Ciudad Autónoma de Buenos Aires, Argentina.
Abstract
AIMS: In this study, we evaluated the antiviral activity of subtilosin, a cyclical peptide isolated from Bacillus amyloliquefaciens, against herpes simplex virus type 2 (HSV-2) in cell cultures and we investigated subtilosin mode of action. METHODS AND RESULTS: We determined, using a virus yield inhibition assay, that noncytotoxic concentrations of subtilosin inhibit HSV-2 replication in Vero cell cultures. Subtilosin strongly inhibited extracellular and total virus production even when it was added at 8 h postinfection indicating that not only virus release but also viral particle formation is impeded by the antiviral peptide. Although viral glycoprotein gD level of expression is not affected by the bacteriocin, an altered pattern of gD intracellular localization was detected by immunofluorescence assay in subtilosin-treated culture. On the other hand, at high concentrations, subtilosin displays virucidal action. CONCLUSIONS: Subtilosin displays antiviral and virucidal actions against HSV-2. The target of subtilosin inhibitory effect would be late stages of the viral replicative cycle such as viral glycoprotein intracellular transport. SIGNIFICANCE AND IMPACT OF THE STUDY: Given its antimicrobial activity and its safety for human tissues, subtilosin could represent a valuable alternative to be considered in the development of new microbicide formulations.
AIMS: In this study, we evaluated the antiviral activity of subtilosin, a cyclical peptide isolated from Bacillus amyloliquefaciens, against herpes simplex virus type 2 (HSV-2) in cell cultures and we investigated subtilosin mode of action. METHODS AND RESULTS: We determined, using a virus yield inhibition assay, that noncytotoxic concentrations of subtilosin inhibit HSV-2 replication in Vero cell cultures. Subtilosin strongly inhibited extracellular and total virus production even when it was added at 8 h postinfection indicating that not only virus release but also viral particle formation is impeded by the antiviral peptide. Although viral glycoprotein gD level of expression is not affected by the bacteriocin, an altered pattern of gD intracellular localization was detected by immunofluorescence assay in subtilosin-treated culture. On the other hand, at high concentrations, subtilosin displays virucidal action. CONCLUSIONS: Subtilosin displays antiviral and virucidal actions against HSV-2. The target of subtilosin inhibitory effect would be late stages of the viral replicative cycle such as viral glycoprotein intracellular transport. SIGNIFICANCE AND IMPACT OF THE STUDY: Given its antimicrobial activity and its safety for human tissues, subtilosin could represent a valuable alternative to be considered in the development of new microbicide formulations.
Authors: M B Wachsman; M E Farías; E Takeda; F Sesma; A P de Ruiz Holgado; R A de Torres; C E Coto Journal: Int J Antimicrob Agents Date: 1999-08 Impact factor: 5.283
Authors: Robert B Belshe; Peter A Leone; David I Bernstein; Anna Wald; Myron J Levin; Jack T Stapleton; Iris Gorfinkel; Rhoda L Ashley Morrow; Marian G Ewell; Abbie Stokes-Riner; Gary Dubin; Thomas C Heineman; Joann M Schulte; Carolyn D Deal Journal: N Engl J Med Date: 2012-01-05 Impact factor: 91.245
Authors: Yevgeniy Turovskiy; Thomson Cheryian; Ammar Algburi; Ruth E Wirawan; Paul Takhistov; Patrick J Sinko; Michael L Chikindas Journal: Infect Dis Obstet Gynecol Date: 2012-09-17
Authors: Don C Des Jarlais; Kamyar Arasteh; Courtney McKnight; David C Perlman; Jonathan Feelemyer; Holly Hagan; Hannah L F Cooper Journal: PLoS One Date: 2014-01-31 Impact factor: 3.240
Authors: Michael L Chikindas; Richard Weeks; Djamel Drider; Vladimir A Chistyakov; Leon Mt Dicks Journal: Curr Opin Biotechnol Date: 2017-08-05 Impact factor: 9.740
Authors: Ashton Harper; Vineetha Vijayakumar; Arthur C Ouwehand; Jessica Ter Haar; David Obis; Jordi Espadaler; Sylvie Binda; Shrilakshmi Desiraju; Richard Day Journal: Front Cell Infect Microbiol Date: 2021-02-12 Impact factor: 6.073